Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Eli Lilly and Company and Precision BioSciences, Inc. announced today that they have entered a research collaboration and exclusive license agreement.
In the IPO announcement, Olema Oncology notes it has granted the underwriters a 30-day option to buy up to 1,650,000 more common stock shares at the IPO price.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Funding raised will be used to take lead candidate into Phase III clinical trials.
Results of Viking Therapeutics’ metabolic disease program exceed all other oral therapies in development in terms of reducing liver fat for nonalcoholic steatohepatitis (NASH) patients, according to Greg Zante, SVP of finance.
With limited doses currently available, the logistics of inoculation are in the works and will certainly require guidance from the outgoing and incoming administrations of Donald Trump and Joe Biden, respectively.
Bill Sibold, executive vice president and head of Sanofi Genzyme, is passionate about fomenting programs that increase the diversity of the workforce in his company and the pharmaceutical industry as a whole.
Lead Pharma has entered into a collaboration and license agreement with Roche, hoping to lead the way in the development of oral small molecules for immune-mediated diseases like rheumatoid arthritis, psoriasis and inflammatory bowel diseases.
The United States continues to headline an annual list of influential science researchers, but that lead is dipping as other global scientists gain recognition from their peers for the work they are conducting.
We have known since early on that diabetes is a complicating risk factor for developing severe illness from the SARS-CoV-2 virus that causes COVID-19. The hypothesis is now being floated by members of the medical community that COVID-19 may cause the disease to return – or potentially a unique version of it.